DEENOVA
20.10.2021 06:02:05 CEST | Business Wire | Press release
Deenova announced today it continues its record-breaking market momentum started during Covid-19 , by winning 2 mechatronic competitive public tenders this Summer for a total of 4 ACCED robotic medication solutions to be operated around the clock at Centre Hospitalier Sainte-Marie Rodez in Occitanie, and Hospital of St Die-des-Vosges near Strasburg.
Loïc Bessin , Managing Director of Deenova in France stated: “When I joined Deenova 3 years ago, the company was a small unit dose specialty business only present in 2 of the Top 5 European markets, having had customers only in France and Italy. I am extremely proud that over the last year alone, we have grown to become the dominant force in the GDP Top 5 healthcare European mechatronics markets for unit-dose, by establishing close partnership with key customers.”
Christophe Jaffuel , Deenova Chief Commercial Officer, stated: “After Deenova multi-million and multi-year recent entries into the two largest European GDP healthcare markets in Germany and the United Kingdom, it is very reassuring to see the continued market success in one of our established countries such as France. Both in terms of total number of customers and number of mechatronic devices, I am very proud that France continues to pave the way for Deenova ´s international growth for 2 consecutive years and counting, highlighting Deenova main differentiating characteristics over our competition in France: patient care crafted for compliance, better safety and therapy control, and 24/7 availability, a key component of customer needs”.
Centre Hospitalier Sainte-Marie Rodez in Occitanie takes care of people with mental illness in Aveyron (4 out of 5 psychiatric sectors) and has 311 beds and complete hospital places (CHSM Rodez, Clinique de Bourran and Clinique de Villefranche-sur-Rouergue) and 115 partial hospitalization beds.
Hospital of St Die-des-Vosges . A benchmark establishment in a hospital community serving a population of 90,000 inhabitants, the Hospital of St Die-des-Vosges constantly strives to improve the quality of care provided to patients. The hospital is committed to carrying out common orientations and activities between the establishments in order to optimise the care and health coverage of the inhabitants of the territory of the Deodatie, serving the community with 452 beds.
Deenova
is the undisputed leading supplier of combined mechatronics (robotic and automation)
solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.
Please visit www.deenova.com
for additional information on its market leading solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005648/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM to Deliver Its First Quantum Computer in South America to Brazil’s Eldorado Research Institute17.9.2026 09:43:00 CEST | Press release
Eldorado will house an IQM Spark at their Campinas headquarters and will also access IQM's 54-qubit cloud-based system, pairing on-premises hardware with larger-scale capability via the cloud. This will enable innovation and growth to scale with their quantum knowledge development. This is the first quantum computer purchase by a private research institute in Brazil, which will enable researchers, engineers, universities, and industry partners to advance research and build capability locally. IQM and Eldorado aim to accelerate quantum adoption across Brazil and South America by building expertise locally and opening the system to Eldorado's network of universities, startups and industry partners. IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced a purchase agreement with the Eldorado Research Institute to deploy its first quantum computer in South America, marking IQM's entry into the region. This press release features multimed
Merz Therapeutics Receives EU/EEA Approval for XEOMIN® for the Treatment of Pediatric Spasticity Associated With Pes Equinus17.9.2026 08:00:00 CEST | Press release
Approval expands XEOMIN use to include the symptomatic treatment of spasticity associated with pes equinus in children and adolescents with cerebral palsy aged 2 to 17 years. Approval includes both children and adolescents who are able to walk and those who are non-ambulant, broadening the population eligible for XEOMIN treatment Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has received approval in the European Union (EU) / European Economic Area (EEA) for XEOMIN® (incobotulinumtoxinA) for the symptomatic treatment of spasticity associated with pes equinus, a condition in which tight calf muscles cause the foot to point downward, in ambulant and non-ambulant children and adolescents with cerebral palsy (CP) aged 2 to 17 years.1,2 This approval expands access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often disruptive symptom in childr
Mediterranean Network for Haemoglobinopathies Launches in Rome, Connecting Clinical Experts and Patient Leaders to Advance Equitable Care17.9.2026 08:00:00 CEST | Press release
Founding members endorse a Declaration of Intent centred on practical collaboration, meaningful patient participation and evidence-based improvement. The Network will address shared challenges including blood supply, unequal access to specialist care and innovation, real-world evidence and European policy change. Avanzanite Bioscience becomes Founding Sponsor to support an independent platform designed to connect expertise, highlight unmet needs and help turn scientific and patient knowledge into practical collaboration. The Mediterranean Network for Haemoglobinopathies (MNfH) was recently launched at Palazzo Wedekind in Rome, bringing together leading clinicians and patient representatives from Cyprus, Greece, and Italy, with the Thalassaemia International Federation (TIF). Supported by Avanzanite Bioscience as Founding Sponsor, the independent regional platform will connect expertise across borders, strengthen the patient voice, and turn shared knowledge into practical initiatives th
IKI Advances Promotional Forecast Accuracy by More Than 10 Points With SymphonyAI17.9.2026 07:03:00 CEST | Press release
Lithuania's second-largest grocer brings AI-driven promotional planning to its network of 250 stores, with early results already showing double-digit gains in forecast accuracy SymphonyAI, a global leader in Vertical AI, today announced that IKI, one of Lithuania's largest grocery retailers, is implementing SymphonyAI's Promotional Evaluation and Promotional Planning solutions across its network of 250 stores, as part of its strategy to strengthen data-driven promotional planning. IKI continuously evaluates opportunities to strengthen its category management and promotional planning capabilities. As promotional programs become increasingly sophisticated, the retailer has invested in advanced analytics and AI-driven forecasting to support data-driven decision making across its business. In its initial work with SymphonyAI across select categories, IKI has seen promotional forecast accuracy improve by more than 10 percentage points, along with a reduction in stock-outs during promotional
Lattice Advances FPGA Design with New Leadership AI-Driven Development Tool, Lattice Prompt17.9.2026 04:00:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today introduced a new leadership AI-powered FPGA development tool for small and mid-range FPGAs that redefines how FPGA developers work across the full design flow. Lattice Prompt pairs with AI agentic tools developers already use, combining them with Lattice design tools, knowledge base, and documentation to turn natural language inputs into validated responses, dramatically accelerating FPGA development while optimizing design performance and capability. "Accelerating time-to-market demands and rising design complexity are putting mounting pressure on FPGA developers to do more with every design cycle," said Esam Elashmawi, Chief Strategy and Marketing Officer, Lattice Semiconductor. "Lattice Prompt gives developers AI-assisted access to the full design flow, grounded in Lattice's validated knowledge, so they can focus on what matters most: building differentiated systems." Lattice Prompt:
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom